Cozzi-Lepri, A;
Prosperi, MC;
Kjær, J;
Dunn, D;
Paredes, R;
Sabin, CA;
Lundgren, JD;
... United Kingdom CHIC/United Kingdom HDRD Study; + view all
(2011)
Can linear regression modeling help clinicians in the interpretation of genotypic resistance data? An application to derive a lopinavir-score.
PLOS One
, 6
(11)
, Article e25665. 10.1371/journal.pone.0025665.
![[thumbnail of 1332693.pdf]](https://discovery.ucl.ac.uk/style/images/fileicons/application_pdf.png) Preview |
PDF
1332693.pdf Download (216kB) |
Abstract
The question of whether a score for a specific antiretroviral (e.g. lopinavir/r in this analysis) that improves prediction of viral load response given by existing expert-based interpretation systems (IS) could be derived from analyzing the correlation between genotypic data and virological response using statistical methods remains largely unanswered.
| Type: | Article |
|---|---|
| Title: | Can linear regression modeling help clinicians in the interpretation of genotypic resistance data? An application to derive a lopinavir-score. |
| Location: | United States |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1371/journal.pone.0025665 |
| Publisher version: | http://dx.doi.org/10.1371/journal.pone.0025665 |
| Language: | English |
| Additional information: | © 2011 Cozzi-Lepri et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. The United Kingdom HIV Drug Resistance Database is partly funded by the Department of Health; the views expressed in the publication are those of the authors and not necessarily those of the Department of Health. Additional support is provided by Bristol-Myers Squibb, Gilead, Pfizer, and Tibotec (a division of Janssen-Cilag Ltd). Primary support for EuroSIDA is provided by the European Commission BIOMED 1 (CT94-1637), BIOMED 2 (CT97-2713), the 5th Framework (QLK2-2000-00773), the 6th Framework (LSHP-CT-2006-018632) and the 7th Framework (FP7/2007-2013, EuroCoord n° 260694) programmes. Current support also includes unrestricted grants by Gilead, Pfizer, and Merck and Co.; The participation of centres from Switzerland was supported by The Swiss National Science Foundation (Grant 108787). Additional funding provided to Deenan Pillay from the EU FP 7 CHAIN grant ( 223131). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. |
| Keywords: | Cohort Studies, Data Interpretation, Statistical, Drug Resistance, Viral, Genotype, HIV, HIV Infections, Health Personnel, Humans, Internet, Linear Models, Lopinavir, Mutation |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Infection and Immunity UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology > MRC Clinical Trials Unit at UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute for Global Health UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute for Global Health > Infection and Population Health |
| URI: | https://discovery.ucl.ac.uk/id/eprint/1332693 |
Archive Staff Only
 |
View Item |
